Product image of Mivacron (Mivacurium Chloride) supplied by GNH India

Mivacron

Active Ingredient:
Mivacurium Chloride
Origin:
EU

Mivacron (Mivacurium Chloride)

Mivacurium Chloride, the active ingredient in Mivacron, is a non-depolarizing neuromuscular blocker presented as an injectable solution for intravenous use. It provides rapid, short‑acting muscle relaxation to facilitate tracheal intubation and to support surgical procedures or mechanical ventilation in adult patients.

GNH India supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to global quality standards and provides reliable logistics for timely delivery across continents. Clients benefit from comprehensive regulatory support and product traceability throughout the supply chain.

Manufacturer / TM Owner

Aspen Pharma Trading Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mivacron is a non‑depolarizing neuromuscular blocker used in the peri‑operative setting to achieve controlled muscle relaxation.

  • Facilitation of tracheal intubation: provides rapid onset muscle relaxation allowing safe placement of the endotracheal tube.
  • Muscle relaxation during surgery: maintains a stable, relaxed surgical field for procedures requiring general anesthesia.
  • Mechanical ventilation support: sustains adequate muscle paralysis for patients requiring prolonged ventilatory assistance.

How It Works

  • Mivacurium chloride acts as a competitive antagonist at nicotinic acetylcholine receptors located on the motor end‑plate of skeletal muscle. By binding to these receptors without activating them, it prevents acetylcholine‑induced depolarization, thereby inhibiting transmission of the nerve impulse and producing a reversible muscle relaxation. The compound belongs to the benzylisoquinolinium class and is hydrolyzed rapidly by plasma cholinesterase, resulting in a short duration of action.

Side Effects

Mivacron may be associated with a range of adverse reactions, varying from mild and transient to severe and life‑threatening.

Common Side Effects

  • Flushing: transient skin redness often observed shortly after injection.
  • Histamine release: mild itching or rash due to mediator release.
  • Transient hypotension: brief decrease in blood pressure that usually resolves without intervention.
  • Bradycardia: slowing of heart rate that may require monitoring.

Serious or Rare Side Effects

  • Anaphylactic reaction: severe allergic response requiring immediate emergency treatment.
  • Prolonged apnea: extended respiratory muscle paralysis leading to the need for assisted ventilation.
  • Severe hypotension: marked drop in blood pressure that can compromise organ perfusion.

Precautions & Warnings

When using Mivacron, clinicians should observe specific precautions to minimize risks and ensure safe administration.

  • Assess cholinesterase activity: evaluate patient’s plasma cholinesterase levels before dosing in cases of suspected deficiency.
  • Monitor neuromuscular function: use quantitative monitoring to gauge depth of blockade and recovery.
  • Cardiovascular caution: use with care in patients with existing hypotension or bradyarrhythmias.
  • Hypersensitivity screening: avoid in individuals with known allergy to mivacurium or related compounds.
  • Adjust for hepatic impairment: consider reduced clearance in severe liver disease.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mivacron can interact with other agents that influence neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid)

  • Concurrent neuromuscular blockers: additive muscle paralysis may result in prolonged ventilation.
  • Aminoglycoside antibiotics: potentiate blockade and increase risk of respiratory failure.
  • Magnesium sulfate: enhances neuromuscular inhibition and may cause severe hypotension.

Moderate Interactions (Monitor Closely)

  • Inhalational anesthetics: synergistic effect on muscle relaxation requiring dose adjustment.
  • Calcium channel blockers: may prolong the duration of action.
  • Anticholinesterase agents: can antagonize the effect of mivacurium, reducing its efficacy.

Frequently Asked Questions

Mivacron is an injectable non‑depolarizing neuromuscular blocking agent used to produce short‑acting muscle relaxation. It facilitates tracheal intubation, provides controlled relaxation during surgical procedures, and supports patients who require mechanical ventilation under general anesthesia.

Mivacurium chloride competitively blocks nicotinic acetylcholine receptors at the motor end‑plate of skeletal muscle. By preventing acetylcholine from depolarizing the muscle membrane, it stops nerve‑muscle transmission, leading to a reversible loss of muscle tone and rapid relaxation.

The dose of Mivacron is individualized by the prescribing clinician. It is calculated based on the patient’s weight, age, clinical condition, and results of neuromuscular monitoring, as well as any known plasma cholinesterase deficiencies.

The pregnancy and lactation categories for Mivacron are not definitively established. Use during pregnancy or while breastfeeding should be considered only if the potential benefit justifies any potential risk to the fetus or infant, and it must be decided by the treating physician.

To order Mivacron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and the necessary import documentation.

Mivacron belongs to the benzylisoquinolinium class, offering a rapid onset and short duration that is metabolized by plasma cholinesterase. Compared with succinylcholine, a depolarizing blocker, Mivacron has a lower risk of hyperkalemia and malignant hyperthermia but may cause more histamine‑related effects.

Mivacron should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use to maintain sterility and potency.

Mivacron is given by intravenous injection or infusion. The initial dose is administered as a bolus, followed by additional doses or a continuous infusion as guided by neuromuscular monitoring to maintain the desired level of muscle relaxation during the procedure.

Serious risks include anaphylactic reactions, prolonged apnea requiring assisted ventilation, and severe hypotension that can compromise organ perfusion. Immediate recognition and appropriate emergency management are essential if any of these events occur.

Mivacron is contraindicated in patients with known hypersensitivity to mivacurium or other benzylisoquinolinium compounds, and it should be used with extreme caution in individuals with severe plasma cholinesterase deficiency, significant hepatic impairment, or uncontrolled cardiovascular instability.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mivacurium Chloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT